MetLife

MET

Market cap $53.5B

Overview Fund Activity

80.46 USD

-0.36

0.45%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

80.46

0.00

0%

1 day

-0.45%

5 days

0.73%

1 month

4.05%

3 months

2.63%

6 months

-2.07%

Year to date

-1.61%

1 year

3.98%

5 years

114.5%

10 years

83.07%

About: MetLife is one of the largest life insurers in the US by assets and provides a variety of life insurance and annuity products. It is organized into six segments: Group Benefits, Retirement and Income Solutions, Asia, Latin America, Europe/Middle East/Africa (EMEA), and MetLife Holdings (products in run-off). Group Benefits and RIS are US-based, contributing to around 48% of the firm's 2024 adjusted earnings. The Asia segment contributes around 25% of earnings, mainly tied to Japan. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of 2024 earnings. The EMEA and MetLife Holdings segments contributed around 4% and 10% of 2024 earnings, respectively.

Employees: 45,000

Financials Life Insurance

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

27% more first-time investments, than exits

New positions opened: 126 | Existing positions closed: 99

1.26% more ownership

Funds ownership: 71.29% [Q1] → 72.56% (+1.26%) [Q2]

10% more repeat investments, than reductions

Existing positions increased: 549 | Existing positions reduced: 500

1% more capital invested

Capital invested by funds: $38.9B [Q1] → $39.2B (+$202M) [Q2]

0% more funds holding

Funds holding: 1,389 [Q1] → 1,392 (+3) [Q2]

30% less call options, than puts

Call options by funds: $554M | Put options by funds: $785M

31% less funds holding in top 10

Funds holding in top 10: 13 [Q1] → 9 (-4) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$91

13% upside

Avg. target

$95

18% upside

High target

$103

28% upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Morgan Stanley Nigel Dally	$94	Overweight Maintained	18 Aug 2025
Keefe, Bruyette & Woods Ryan Krueger	$92	Outperform Maintained	11 Aug 2025
Jefferies Suneet Kamath	$103	Buy Maintained	11 Aug 2025
UBS Brian Meredith	$91	Buy Maintained	7 Aug 2025
Wells Fargo Elyse Greenspan	$97	Overweight Maintained	10 Jul 2025
JP Morgan Jimmy Bhullar	$95	Overweight Maintained	8 Jul 2025
Barclays Alex Scott	$94	Overweight Maintained	7 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about MET published over the past 30 days

MetLife Recommends Shareholders Reject “Mini-Tender” Offer by Potemkin Limited

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has received notice of an unsolicited mini-tender offer by Potemkin Limited (“Potemkin”) to purchase up to 10,000 shares of MetLife, Inc. common stock from MetLife shareholders. The offer is for approximately 0.00002 percent of MetLife's shares of common stock outstanding as of August 31, 2025. Potemkin's offer price of $53.00 per share is approximately 34.42 percent lower than the $80.82 closing price of MetLife commo.

MetLife Recommends Shareholders Reject “Mini-Tender” Offer by Potemkin Limited

Zacks Investment Research

MET Adds Cancer Support Benefit to Upgrade Critical Illness Plan

MetLife enhances its Critical Illness Insurance with a new Cancer Support benefit, offering enhanced care and guidance from Private Health Management experts for patients starting in 2026.

MET Adds Cancer Support Benefit to Upgrade Critical Illness Plan

MetLife Launches Cancer Support Benefit to Help Employees Understand and Navigate Care Options as Cancer Diagnoses Continue to Rise

NEW YORK--(BUSINESS WIRE)--MetLife has introduced a new Cancer Support benefit to help employees with personalized advice and attention from diagnosis to treatment and through recovery. Through a strategic relationship with Private Health Management, a leader in complex care navigation, MetLife will expand its Critical Illness Insurance offering to provide a more robust cancer benefit, including access to top oncology specialists, tech-enabled and expert-led coordination, and patient counseling.

MetLife Launches Cancer Support Benefit to Help Employees Understand and Navigate Care Options as Cancer Diagnoses Continue to Rise

MetLife, Inc. (MET) Presents At KBW Insurance Conference 2025 Transcript

MetLife, Inc. (NYSE:MET ) KBW Insurance Conference 2025 September 3, 2025 10:05 AM EDT Company Participants Michel Khalaf - CEO, President & Director John McCallion - Executive VP, CFO & Head of Investment Management Conference Call Participants Ryan Krueger - Keefe, Bruyette, & Woods, Inc., Research Division Presentation Ryan Krueger Managing Director of Equity Research I'm Ryan Krueger, Life Insurance Analyst at KBW. It's great to have MetLife back with us again this year.

MetLife, Inc. (MET) Presents At KBW Insurance Conference 2025 Transcript

MetLife Announces Full Redemption of Series G Preferred Stock

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it will redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, liquidation preference of $1,000 per share ("Series G Preferred Stock"), at a redemption price of $1,000 per share of Series G Preferred Stock. All outstanding shares of Series G Preferred Stock will be redeemed on the dividend payment date of September 15, 2025. Regular dividends on the outstanding shares of Ser.

MetLife Announces Full Redemption of Series G Preferred Stock

MetLife Investment Management Names Geert Henckens Global Head of Private Fixed Income

WHIPPANY, N.J.--(BUSINESS WIRE)--MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced that it has named Geert Henckens global head of Private Fixed Income. Henckens will expand his role to lead teams that originate and manage a broad array of private asset investments that aim to offer clients attractive relative value, portfolio diversification and potential downside protection. MIM has a longstanding track record of ori.

MetLife Investment Management Names Geert Henckens Global Head of Private Fixed Income

100 Sustainable Dividend Dogs: 47 "Safer", 3 Ideal August Buys, And 7 To Watch

I analyze Barron's top 100 sustainable companies, focusing on dividend payers and using the dogcatcher yield-based strategy to identify value opportunities. Seven out of 83 dividend-paying sustainable stocks currently meet the ideal of annual dividends from a $1K investment exceeding their share price, signaling potential buys. Analyst targets project 20.21% to 45.71% net gains for the top ten ESG dividend stocks by August 2026, with average risk below the market.

100 Sustainable Dividend Dogs: 47 "Safer", 3 Ideal August Buys, And 7 To Watch

MetLife Declares Third Quarter 2025 Preferred Stock Dividends

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has declared the following preferred stock dividends: Quarterly dividend of $0.35263005 per share on the company's floating rate non-cumulative preferred stock, Series A, with a liquidation preference of $25 per share (NYSE: MET PRA). Semi-annual dividend of $29.375 per share on the company's 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a liquidation preference of $1,000 per share. Quart.

MetLife Declares Third Quarter 2025 Preferred Stock Dividends

MetLife CEO Michel Khalaf and CFO John McCallion to Speak at the 2025 Keefe, Bruyette & Woods Insurance Conference

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that Michel Khalaf, president and chief executive officer, and John McCallion, executive vice president and chief financial officer, and head of MetLife Investment Management, will participate in a fireside chat at the 2025 Keefe, Bruyette & Woods Annual Insurance Conference on Wednesday, Sept. 3, 2025, from 10:05 a.m. to 10:45 a.m. (ET). A live audio webcast of the presentation will be available at https://event.summitcas.

MetLife CEO Michel Khalaf and CFO John McCallion to Speak at the 2025 Keefe, Bruyette & Woods Insurance Conference

CNBC Television

Trade Tracker: Brian Belski buys more Goldman Sachs, MetLife and FedEx

Brian Belski, Chief Investment Strategist at BMO Capital Markets, joins 'Halftime Report' to detail his latest portfolio moves.

Trade Tracker: Brian Belski buys more Goldman Sachs, MetLife and FedEx

See News Rankings

Charts implemented using Lightweight Charts™